Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cosmina Hogea

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
The Journal of Adolescent Health : Official Publication of the Society for Adolescent Medicine|May 20, 2019
Meningococcal Vaccination Among Adolescents in the United States: A Tale of Two Age PlatformsSamantha K Kurosky, Elizabeth Esterberg, Debra E Irwin, et al.
Vaccine|August 25, 2019
Meningococcal-group B (MenB) vaccine series completion and adherence to dosing schedule in the United States: A retrospective analysis by vaccine and payer typeElizabeth Packnett, Debra E Irwin, Patricia Novy, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 13, 2022
An Epidemiology Model for Estimating the Numbers of US Patients With Multiple Myeloma by Line of Therapy and Treatment ExposureAndreas Nikolaou, Cosmina Hogea, Yevgeniy Samyshkin, et al.
Leukemia Research|September 28, 2024
Patient-centric care in myelodysplastic syndromes: A global systematic literature review and gap analysisEdward P Armstrong, Duska M Franic, Daniel C Malone, et al.
Clinicoeconomics and Outcomes Research : CEOR|September 17, 2021
Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United StatesAnshul Shah, Jonathan C Tosh, Apoorva Ambavane, et al.
Future Oncology (London, England)|July 8, 2022
Physician treatment preferences for relapsed/refractory multiple myeloma: a discrete choice experimentLaurie Batchelder, Stephanie Philpott, Victoria Divino, et al.
Pharmacoeconomics - Open|August 23, 2025
Identifying Potential Gaps in Care for Patients with Higher-Risk Myelodysplastic Syndromes in a Large US Health SystemKristin J Moore, Nicole M Engel-Nitz, Peter McMahon, et al.
Advances in Therapy|September 25, 2021
DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple MyelomaThibaud Prawitz, Rakesh Popat, Attaya Suvannasankha, et al.
Plos One|January 26, 2019
Biased efficacy estimates in phase-III dengue vaccine trials due to heterogeneous exposure and differential detectability of primary infections across trial armsGuido España, Cosmina Hogea, Adrienne Guignard, et al.
Cancer Management and Research|June 30, 2025
Experiences with Higher-Risk Myelodysplastic Syndromes and Improving Patient-Centered Treatment Decision-Making: A Qualitative Study of Patients, Caregivers, and ProvidersMelissa Culhane Maravic, Natalie Land, Nadya Prood, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
The Journal of Adolescent Health : Official Publication of the Society for Adolescent Medicine|May 20, 2019
Meningococcal Vaccination Among Adolescents in the United States: A Tale of Two Age PlatformsSamantha K Kurosky, Elizabeth Esterberg, Debra E Irwin, et al.
Vaccine|August 25, 2019
Meningococcal-group B (MenB) vaccine series completion and adherence to dosing schedule in the United States: A retrospective analysis by vaccine and payer typeElizabeth Packnett, Debra E Irwin, Patricia Novy, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 13, 2022
An Epidemiology Model for Estimating the Numbers of US Patients With Multiple Myeloma by Line of Therapy and Treatment ExposureAndreas Nikolaou, Cosmina Hogea, Yevgeniy Samyshkin, et al.
Leukemia Research|September 28, 2024
Patient-centric care in myelodysplastic syndromes: A global systematic literature review and gap analysisEdward P Armstrong, Duska M Franic, Daniel C Malone, et al.
Clinicoeconomics and Outcomes Research : CEOR|September 17, 2021
Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United StatesAnshul Shah, Jonathan C Tosh, Apoorva Ambavane, et al.
Future Oncology (London, England)|July 8, 2022
Physician treatment preferences for relapsed/refractory multiple myeloma: a discrete choice experimentLaurie Batchelder, Stephanie Philpott, Victoria Divino, et al.
Pharmacoeconomics - Open|August 23, 2025
Identifying Potential Gaps in Care for Patients with Higher-Risk Myelodysplastic Syndromes in a Large US Health SystemKristin J Moore, Nicole M Engel-Nitz, Peter McMahon, et al.
Advances in Therapy|September 25, 2021
DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple MyelomaThibaud Prawitz, Rakesh Popat, Attaya Suvannasankha, et al.
Plos One|January 26, 2019
Biased efficacy estimates in phase-III dengue vaccine trials due to heterogeneous exposure and differential detectability of primary infections across trial armsGuido España, Cosmina Hogea, Adrienne Guignard, et al.
Cancer Management and Research|June 30, 2025
Experiences with Higher-Risk Myelodysplastic Syndromes and Improving Patient-Centered Treatment Decision-Making: A Qualitative Study of Patients, Caregivers, and ProvidersMelissa Culhane Maravic, Natalie Land, Nadya Prood, et al.
Pageof 4